- Conditions
- Adult Burkitt Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, Epcoritamab, Etoposide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
- Procedure · Drug · Biological
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 235
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Leucovorin Calcium, Lumbar Puncture, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate, X-Ray Imaging
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 488 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 531
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 328 more
- Conditions
- Recurrent Acute Myeloid Leukemia
- Interventions
- Venetoclax, Decitabine, Cedazuridine, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
- Drug · Procedure
- Lead sponsor
- Sanjay Mohan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 478
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 354 more
- Conditions
- Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Venetoclax
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 21
- States / cities
- Duarte, California • Irvine, California • Aventura, Florida + 16 more
- Conditions
- Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
- Interventions
- Tagraxofusp, Azacitidine (AZA), Venetoclax
- Drug
- Lead sponsor
- Jacqueline Garcia, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Acalabrutinib, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Obinutuzumab, Questionnaire Administration, Tafasitamab
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Punch Biopsy, Questionnaire Administration, Ruxolitinib, Venetoclax
- Drug · Procedure · Other
- Lead sponsor
- Jennifer Saultz
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Portland, Oregon • Dallas, Texas
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic Large Cell Lymphoma, Burkitt Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Filgrastim, Fludarabine, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Treosulfan, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Biospecimen Collection, Computed Tomography, Positron Emission Tomography
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Gilteritinib, Revumenib, Echocardiography Test, Multigated Acquisition Scan
- Procedure · Drug
- Lead sponsor
- Uma Borate
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Chapel Hill, North Carolina • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
- Conditions
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Inotuzumab Ozogamicin, Lumbar Puncture, Ponatinib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 278
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 171 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Columbus, Ohio
- Conditions
- Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Belantamab Mafodotin, Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Biospecimen Collection, Skeletal Survey X-Ray, Low Dose Computed Tomography of the Whole Body, Bone Marrow Aspiration, Bone Marrow Biopsy
- Biological · Drug · Other + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
- Procedure · Other · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2075
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 123 more
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia
- Interventions
- FOLR1 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine, Pheresis, Positron Emission Tomography
- Biological · Procedure · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 6 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test, Multigated Acquisition Scan, UAE Inhibitor TAK-243
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Chicago, Illinois • Columbus, Ohio + 1 more
- Conditions
- Hematologic Malignancy
- Interventions
- Standard of Care, Virtual Reality intervention
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Venetoclax, Zanubrutinib
- Procedure · Drug
- Lead sponsor
- Kerry Rogers
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Bone Marrow Biopsy Procedures
- Interventions
- OnControl Bone Marrow Biopsy and Aspiration System, Manual bone marrow sampling device
- Device
- Lead sponsor
- Vidacare Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
- Interventions
- Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Neuroblastoma, Refractory Childhood Osteosarcoma, Refractory Neuroblastoma, Refractory Osteosarcoma
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine Phosphate, GD2-CAR-expressing Autologous T-lymphocytes, Imaging Procedure, Magnetic Resonance Imaging of the Heart, Multigated Acquisition Scan, Questionnaire Administration
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 40 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2040
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Palo Alto, California • Aurora, Colorado + 3 more
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 337
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 260 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 225
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 179 more
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Magnetic Resonance Imaging, Obinutuzumab, Venetoclax
- Procedure · Other · Biological + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 7
- States / cities
- Duarte, California • Irvine, California • Long Beach, California + 4 more